1. Most Discussed
  2. Gainers & Losers

biotech best performing sectors

  1. croupier

    5,447 posts.
    October 2002 Stock Report

    The October 2002 Stock Report, published by Recombinant Capital and Signals, is the 29th in a series. It includes detailed financial data on 235 publicly traded biotechnology stocks, based on their closing prices on October 31, 2002.

    (To access the September 2002 Stock Report, click here. For the others -- February 2000 through August 2002 -- click here to go to Signals' Table Of Contents. [We did not publish stock reports for the June 2001 - September 2001 time frame.] All the Stock Reports are listed under the Signals vs. Noise section. The spreadsheets underlying these articles are quite large, so please be patient while you download them.)

    We've classified the companies on the list into 18 separate categories, based largely on either technology or disease focus. These categories can be found in the table that follows, which provides a summary of the underlying data and the average values (the sum of all values divided by the number of values) for each. Because the average value tends to be distorted when there are extreme values in a set (as occurs in the biotech stocks as a group and even within groups), we've also calculated the median (mid-point) for each set of data and for the entire group. We believe that the median values reflect a more realistic financial profile for the biotech stocks.

    If you wish to access the entire spreadsheet (HTML 221k), just click here (and remember, it's a large spreadsheet and takes time to download. Don't despair if your screen seems to remain forever blank after the download; it might take a minute or so for the spreadsheet to appear.) If you wish to access the section of the spreadsheet that concerns a specific category (i.e., cancer or gene therapy), click on that category in the summary table below.

    Company % 52 wk high on 10/31/02 % change from 10/26/01 Market cap ($M) Cash & Mkt. Sec. ($M) Tech value ($M) Tech value/staff ($M) Est. burn rate ($M) Survival index (yrs) Equity multiple
    1st
    Generation
    Genomics
    Average:
    Median:
    22%







    Genomic Supply
    Average:
    Median:
    35%
    GenomicTargets
    Average:
    Median:
    25%

    Agbio/Enviro.
    Average:
    Median:
    54%
    Autoimmune
    Average:
    Median:
    43%
    Cancer
    Average:
    Median:
    30%
    Cardiovascular
    Average:
    Median:
    49%

    Chemistry
    Average:
    Median:
    41%
    Average:
    Median:
    37%
    Delivery
    Average:
    Median:
    34%
    Diagnostic/Imaging
    Average:
    Median:
    47%
    Gene Therapy
    Average:
    Median:
    29%
    Infection
    Average:
    Median:
    43%

    Metabolic
    Average:
    Median:
    43%

    Other
    Average:
    Median:
    47%

    Revenue-Driven
    Average:
    Median:
    66%
    Screening
    Average:
    Median:
    37%
    Wound
    Average:
    Median:
    42%
    Grand
    Average:
    Median:
    39%


    Cash flow are best!!

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top